 |
  |
|
|
APRIL 19,
2008
|
|
|
|
OVERVIEW The goal of this conference is to increase the participant’s knowledge of current advances in the diagnosis and management of cardiovascular disease with an emphasis on both interventional and non-interventional modalities. TARGET AUDIENCE This annual premier event features local and nationally recognized faculty and focuses on the specific needs of those in primary care, internal medicine, family practice, and general cardiology. OBJECTIVES At the conclusion of this activity, participants should be able to:
ACCREDITATION PHYSICIAN Accreditation Statement UNT Health Science Center is accredited by the American Osteopathic Association to award continuing medical education to physicians. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of North Texas Health Science Center of Fort Worth Office of Professional and Continuing Education (PACE) and The Camenae Group, Inc. The UNTHSC Office of PACE is accredited by the ACCME to provide continuing medical education for physicians. Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit Designation UNT Health Science Center anticipates this program for 5.5 hours in Category 2A CME credit hours, pending approval by the AOA CCME. The University of North Texas Health Science Center designates this educational activity for a maximum of 5.5 AMA PRA Category 1 credits TM.
NURSE PRACTITIONER Accreditation Statement This program has been approved for 5.58 contact hours of continuing education (which includes 2.25 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 0803162. Credit Designation This activity provides 5.58 contact hours.
NURSING Accreditation Statement
The Camenae
Group, Inc. is an approved provider of continuing nursing education by the
Texas Nurses Association, an accredited approver by the American Nurses
Credentialing Center’s Commission on Accreditation. Credit Designation This activity provides 6.0 contact hours.
CERTIFIED CASE MANAGER This program has been approved by the Commission for Case Manager Certification for 5.75 Clock Hours.
MORE INFORMATION
For further
information or assistance with special needs, please contact the Camenae
Group, Inc.
|
AGENDA 7:30 AM Registration & Continental Breakfast
8:00
Welcome, Overview & Introductory
Remarks
8:10 Treatment of Dyslipidemias: Beyond LDL
9:10
The Future of Congestive Heart Failure Treatment 10:10 Break
10:30
Management
of Pre-Hypertension 11:30 Lunch
12:50 PM
Controversies in Anti-Platelet Therapies in ACS
1:50
Carotid Stenting
2:30
Left Main Stenting
3:10
Questions and Answer, Closing Remarks
FACULTY COURSE DIRECTOR Diagnostic and Interventional Cardiologist Baylor Jack and Jane Hamilton Heart and Vascular Hospital • Dallas, TX
Dean A. Bramlet, MD, FACC, FACP, FAHA
Diplomat of
Clinical Lipidology
Medical Director
and Founder
Assistant
Professor of Medicine
Director,
Coronary Care Unit
Vascular and Cardiology
Interventionalist Dallas, TX
C. Venkata S. Ram, MD, MACP, FACC
Professor of
Internal Medicine
Vice President American Society of Hypertension, Inc. (ASH) Director, Texas Blood Pressure Institute Director, Clinical Research Institute Dallas Nephrology Associates • Dallas, TX
Robert C. Stoler, MD, FACC, FSCAI
Clinical and
Interventional Cardiologist
Clyde W. Yancy, MD, FACC, FAHA, FACP
Medical Director
Chief of
Cardiothoracic Transplantation
Above faculty subject to change- all scheduled to appear at time of release. Disclosure by faculty members of significant support or substantial financial relationships between presenters and commercial entities is required in relevant situations whether or not there is direct commercial support for the CE activity. In addition, faculty must disclose “off-label” uses of substances or products included in the presentation that are not approved by the US Food and Drug Administration and/or the status of substances or products that are being investigated for such use.
ACKNOWLEDGEMENTS The following have provided educational grants in support of this activity:
Abbott Astra Zeneca Boehringer Ingleheim Boston Scientific Cardiac Rhythm Management Cardionet ev3 Lippincott Williams & Wilkins Medtronic CRDM Medtronic Vascular Merck Novartis Pfizer Philips Medical Schering Plough The Medicines Company
|
|
 |
This event provided by
|
|
